脐带源与骨髓源干细胞移植治疗神经系统病变的安全性比较(英文)

背景:对于临床常用于治疗神经系统病变的脐带源干细胞和骨髓源干细胞的安全性,尚无较为全面研究。目的:比较脐带源和骨髓源干细胞移植治疗神经系统病变的安全性。方法:将214例神经系统病变患者随机分为两组,分别通过局部、静脉、脑脊液循环途径,移植脐带源干细胞或骨髓源干细胞。每例患者植入干细胞(5～12)×108个。结果与结论:两组患者干细胞移植治疗后淋巴细胞计数、谷丙转氨酶、谷草转氨酶、IgA、IgM,与治疗前相比有显著性意义(P<0.01),组间比较差异无显著性意义(P>0.05)。两组患者治疗后脑脊液白细胞和红细胞均出现异常,高于正常值,组间比较差异无显著性意义(P>0.05)。两组患者潘台实验阳性、不良反应发生率组间相比差异无显著性意义(P>0.05)。说明脐带源和骨髓源干细胞移植治疗神经系统病变的安全性无明显差别。

Safety of umbilical cord versus bone marrow-derived mesenchymal stem cells transplantation for the treatment of nervous system lesions *

BACKGROUND:The comparative study concerning the safety of umbilical cord and bone marrow-derived mesenchymal stem cells transplantation for the treatment of nervous system lesions is insufficient.OBJECTIVE:To assess the safety of umbilical cord and bone marrow-derived mesenchymal stem cells transplantation for treatment of nervous system lesions.METHODS:A total of 214 cases with neuropathy were randomly divided into A,B groups.Patients in the A group received umbilical cord derived stem cell transplantation,and those in the B group received bone marrow-derived mesenchymal stem cells transplantation.Totally(5-12)×108 stem cells were transplanted into each patient.RESULTS AND CONCLUSION:The count of lymphocytes,alanine aminotransferase,aspartate aminotransferase,IgA,and IgM were increased compared with those before treatment in both groups(P < 0.01);However there were no significant differences between two groups(P > 0.05).Moreover,white blood cell count and red blood cell count in cerebrospinal fluid of all patients were significantly greater than the normal level.There were no significant differences between two groups(P > 0.05).No significant differences of the positive rate of Pandy test and the incidence rate of adverse effect were found in both groups(P > 0.05).The safety of umbilical cord and bone marrow-derived mesenchymal stem cell transplantation for treatment of nervous system lesions showed no marked differences.